K Number
K994399
Device Name
INSTANT-VIEW AMPHETAMINE URINE DIP STRIP TEST
Date Cleared
2000-08-04

(220 days)

Product Code
Regulation Number
862.3100
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
Instant-View™ Amphetamine Urine Dip Strip Test is a qualitative immunoassay device intended to be used for detecting Amphetamine in human urine at a cutoff level of 1000 ng/ml. It is for health care professional use only. Instant-View Amphetamine Urine Dip Strip Test is a qualitative one step lateral flow, competitive binding immunoassay device intended to be used to detect amphetamine in human urine at a cutoff level of 1000 ng/ml. It is intended for health care professional use only. This test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrophotometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse, particularly when preliminary positive results are used.
Device Description
This test is a one-step lateral flow chromatographic immunoassay.
More Information

Not Found

No
The device description and performance studies indicate a standard lateral flow immunoassay, with no mention of AI or ML technologies.

No
The device is described as an immunoassay device intended for detecting amphetamine in human urine, which is a diagnostic purpose, not a therapeutic one.

Yes

The device is intended to detect Amphetamine in human urine, providing a preliminary analytical test result that can be used for clinical consideration and professional judgment. While it requires confirmation, its purpose is to provide an initial assessment of a medical condition (presence of a substance in the body).

No

The device description explicitly states it is a "one-step lateral flow chromatographic immunoassay," which is a physical test strip, not software.

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use explicitly states it is for "detecting Amphetamine in human urine." This involves testing a sample taken from the human body (urine) in vitro (outside the body) to provide information about a physiological state (presence of amphetamine).
  • Device Description: It is described as a "qualitative immunoassay device" and a "one-step lateral flow chromatographic immunoassay." These are common types of IVD tests.
  • Anatomical Site: The sample is "human urine," which is a biological specimen.
  • Performance Studies: The document describes performance studies comparing the device to a legally marketed test device and evaluating its accuracy in a clinical laboratory and physician's offices. This type of evaluation is typical for IVD devices to demonstrate their performance characteristics.
  • Predicate Device: A predicate device (K971218, QuikStrip OneStep Amphetamine Test) is listed, which is a requirement for submitting a 510(k) premarket notification for a medical device, including IVDs.

All these factors align with the definition and characteristics of an In Vitro Diagnostic device.

N/A

Intended Use / Indications for Use

The Instant-View™ Amphetamine Urine Dip Strip Test is a qualitative immunoassay device intended to be used for detecting Amphetamine in human urine at a cutoff level of 1000 ng/ml. It is for health care professional use only.
Instant-View Amphetamine Urine Dip Strip Test is a qualitative one step lateral flow, competitive binding immunoassay device intended to be used to detect amphetamine in compotitive binaning initiality of 1000 ng/ml. It is intended for health care professional use only.
This test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrophotometry (GC/MS) is the preferred confirmatory method. mutographyrilates opposad professional judgment should be applied to any drug of abuse, particularly when preliminary positive results are used.

Product codes

DKZ

Device Description

This test is a one-step lateral flow chromatographic immunoassay.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

human urine

Indicated Patient Age Range

Not Found

Intended User / Care Setting

health care professional use only.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

The correlation of results from the Instant-View™ Amphetamine Urine Dip Strip Test, and the legally marketed test device compared, is higher than 94.2 %. The results from all three POL sites agreed 95.0 %. The Accuracy Evaluation results from the Clinical Laboratory and the three Physician's Offices conducted by persons with diverse educational backgrounds and working experience agreed 92.2 % with the results expected.

Key Metrics

Correlation of results: higher than 94.2%
Agreement from all three POL sites: 95.0%
Accuracy Evaluation agreement: 92.2%

Predicate Device(s)

K971218

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 862.3100 Amphetamine test system.

(a)
Identification. An amphetamine test system is a device intended to measure amphetamine, a central nervous system stimulating drug, in plasma and urine. Measurements obtained by this device are used in the diagnosis and treatment of amphetamine use or overdose and in monitoring levels of amphetamine to ensure appropriate therapy.(b)
Classification. Class II (special controls). An amphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

0

Alfa Scientific Designs, Inc.

11494 Sorrento Valley Road, Suite M San Diego, CA 92121

510(K) Summary

In accordance with the Safe Medical Devices Act of 1990, a 510(K) summary is provided as outlined in 21 CFR 807.92.

SubmitterName: Alfa Scientific Designs, Inc.
Address: 11494 Sorrento Valley Road, Suite M
San Diego, CA 92121
Telephone: (858) 350-9798
Fax: (858) 350-9709
Email: asdi@worldnet.att.net
Device NameTrade Name: Instant-View™ Amphetamine Urine Dip Strip Test
Common Name: Amphetamine Test
Classification Name: 21 CFR 862.3100, Class II
Predicate DeviceThe Instant-View™ Amphetamine Urine Dip Strip Test is
substantially equivalent to other legally marketed devices
for the similar intended use. The device used for
comparison study is QuikStrip OneStep Amphetamine Test,
manufactured by Syntron Bioresearch, Inc. with 510(K) #:
K971218, Date of Approval: 05/30/97.
Device DescriptionThis test is a one-step lateral flow chromatographic
immunoassay.
Intended UseThe Instant-View™ Amphetamine Urine Dip Strip Test is a
qualitative immunoassay device intended to be used for
detecting Amphetamine in human urine at a cutoff level of
1000 ng/ml. It is for health care professional use only.
Summary of the
Similarities to the
Predicate Device• Intended Use:
Both devices are intended to detect amphetamine in
human urine at a cutoff level of 1000 ng/ml.
• Interpretation of results:
The appearance of only one line - C line indicates a
positive result, and that the amphetamine level at a cutoff
level of 1000 ng/ml or higher. And, the appearance of
two lines – both C line and T line indicates a negative
result, and that the amphetamine level is below 1000
ng/ml. Technological Characteristics: Both devices are one step, qualitative, competitive binding immunoassay test, utilizing the basic immunochemical sandwich assay principle of recognition and formation of specific Amphetamine/
Antibody/Amphetamine complexes.
Discussion and
ConclusionThe correlation of results from the Instant-View™ Amphetamine Urine Dip Strip Test, and the legally marketed test device compared, is higher than 94.2 %. The results from all three POL sites agreed 95.0 %. The Accuracy Evaluation results from the Clinical Laboratory and the three Physician's Offices conducted by persons with diverse educational backgrounds and working experience agreed 92.2 % with the results expected. Based on the results of the Performance Characteristics and Comparison Studies, it may be concluded that the Instant-View™ Amphetamine Urine Dip Strip Test is suitable for use by health care professionals with diverse educational backgrounds and work experiences, and it is substantially equivalent to the existing legally marketed device.

1

2

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is a stylized image of three overlapping lines that resemble a person embracing another person, which is a common symbol used by the department to represent its mission of providing essential human services.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

4 2000 AUG

Ms. Rhoda Filipina OA Manager Alfa Scientific Designs, Inc. 11494 Sorrento Valley Road Suite M San Diego, California 92121

K994399 Re:

Trade Name: Instant-View Amphetamine Urine Dip Strip Test Regulatory Class: II Product Code: DKZ Dated: July 7, 2000 Received: July 10, 2000

Dear Ms. Filipina:

We have reviewed your Section 510(k) notification of intent to market the device referenced we nave reviewed your becamer of (s) = is substantially equivalent (for the indications for use above and we nave determined and arketed predicate devices marketed in interstate commerce stated in the encrosure) to regary miles of the Medical Device Amendments, or to devices that prior to may 20, 1970, are endance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls Cosments Act. The Act. The general controls provisions of the Act include requirements for annual provisions of the Free. " rivers, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations (1 renance ripptoval), it they of bacyer . Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to mspections, uit Food and Drag innay result in regulatory action. In addition, FDA may publish comply with the Grill resorts concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

3

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

Page 1 of 1

K994399 510(k) Number (if known):

Device Name: Instant-View Amphetamine Urine Dip Strip Test
Device Name: _____________________________________________________________________________________________________

Indications For Use:

Instant-View Amphetamine Urine Dip Strip Test is a qualitative one step lateral flow, competitive binding immunoassay device intended to be used to detect amphetamine in compotitive binaning initiality of 1000 ng/ml. It is intended for health care professional use only.

This test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrophotometry (GC/MS) is the preferred confirmatory method. mutographyrilates opposad professional judgment should be applied to any drug of abuse, particularly when preliminary positive results are used.

Cooges

(Division Sign-Off)
Division of Clinical Laboratory Devices/
510(k) Number K994399
Devices

(Please do not WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter-Use (Optional Format 1-2-96)